Citations

Showing 10 of 108083 citations.

Ischaemic stroke
Brott, Thomas G. , Meschia, James F.

Mayo Clinic

European Journal of Neurology | August 11, 2017 | Volume: 25 | Issue: 1 | Pages: 35-40

10.1111/ene.13409 | PMID 28800170 Get It

There are about 25.7 million stroke survivors worldwide. Ischaemic stroke remains the most common type of stroke. Numerous modifiable risk factors have been identified, including behaviors such as cigarette smoking and sedentary lifestyle and treatable medical comorbidities such as hypertension, hyperlipidemia and atrial fibrillation. Once considered irreversible, acute ischaemic stroke is now amenable to acute medical and endovascular therapies to reduce infarct volume. Many advances are expected in the years to come, particularly in the areas of prevention and recovery.
Short‐term outcomes of atrial flutter ablation
Tripathi, Byomesh , Arora, Shilpkumar , Mishra, Abhishek , Kundoor, Vishwa, Lahewala, Sopan , Kumar, Varun , Shah, Mahek , Lakhani, Dhairya A. , Shah, Harshil , Patel, Nilay , Patel, Nileshkumar , Dave, Mihir, Deshmukh, Abhishek , Sattur, Sudhakar, Gopalan, Radha , Lakhani, Dhairya

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 11, 2017 | Volume: 28 | Issue: 11 | Pages: 1275-1284

10.1111/jce.13311 | PMID 28800179 Get It

AbstractBackgroundUnderstanding the factors associated with early readmissions following atrial flutter (AFL) ablation is critical to reduce the cost and improving the quality of life in AFL patients.MethodThe study cohort was derived from the national readmission database 2013–2014. International Classification of Diseases, 9th Revision (ICD‐9‐CM) diagnosis code 427.32 and procedure code 37.34 were used to identify AFL and catheter ablation, respectively. The primary and secondary outcomes were 90‐day readmission and complications including in‐hospital mortality. Cox proportional regression and hierarchical logistic regression were used to generate the predictors of primary and secondary outcomes respectively. Readmission causes were identified by ICD‐9‐CM code in primary diagnosis field of readmissions.ResultReadmission rate of 18.19% (n = 1,010 with 1,396 readmissions) was noted among AFL patients (n = 5552). Common etiologies for readmission were heart failure (12.23%), atrial fibrillation (11.13%), atrial flutter (8.93%), respiratory complications (9.42%), infections (7.4%), bleeding (7.39%, including GI bleed–4.09% and intracranial bleed–0.79%) and stroke/TIA (1.89%). Multivariate predictors of 90‐day readmission (hazard ratio, 95% confidence interval, P value) were preexisting heart failure (1.30, 1.13–1.49, P < 0.001), chronic pulmonary disease (1.37, 1.18–1.58, P < 0.001), anemia (1.23, 1.02–1.49, P = 0.035), malignancy (1.87, 1.40–2.49, P < 0.001), weekend admission compared to weekday admission (1.23, 1.02–1.47, P = 0.029), and length of stay (LOS) ≥5 days (1.39, 1.16–1.65, P < 0.001). Note that 50% of readmissions happened within 30 days of discharge.ConclusionCardiac etiologies remain the most common reason for the readmission after AFL ablation. Identifying high risk patients, careful discharge planning, and close follow‐up postdischarge can potentially reduce readmission rates in AFL ablation patients.
Laparoscopic Splenectomy for Massive Splenomegaly: Does Size Matter?
Tsamalaidze, Levan , Stauffer, John , Permenter, S., Asbun, Horacio J. , Permenter, Samantha L, A Stauffer, John

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | August 11, 2017 | Volume: 27 | Issue: 10 | Pages: 1009-1014

10.1089/lap.2017.0384 | PMID 28799827 Get It

Faculty Opinions recommendation of Musashi 1 regulates the timing and extent of meiotic mRNA translational activation by promoting the use of specific CPEs.
Liu, Qiuying , Hu, Wenqian

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 11, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727815114.793535191 Get It

Rhinology‐specific priority setting for quality improvement: a modified Delphi study from the Quality Improvement Committee of the American Rhinologic Society
Rudmik, Luke , Mattos, José L. , Stokken, Janalee K., Manes, R. Peter , Setzen, Michael, Lee, Jivianne, Schneider, John S. , Stokken, Janalee K. , Soler, Zachary M. , Higgins, Thomas S , Lee, Jivianne T. , Carlson, Matthew L , Mattos, Jose

Mayo Clinic

International Forum of Allergy & Rhinology | August 11, 2017 | Volume: 7 | Issue: 10 | Pages: 937-944

10.1002/alr.21998 | PMID 28799731 Get It

BackgroundImproving the quality of healthcare is a complex and resource intensive process. To optimize the allocation of scarce resources, quality improvement (QI) should focus on high‐value diseases that will produce the largest improvement in health system performance. Given the breadth and multidisciplinary nature of sinonasal disease management, the purpose of this study was to transparently develop a prioritized list of sinonasal diseases for QI from the perspective of the specialty of rhinology and the American Rhinologic Society (ARS).MethodsThe RAND modified Delphi methodology was used to rank the priority of nine sinonasal disease categories from 1 (lowest priority) to 9 (highest priority). Two rounds of ranking along with a teleconference meeting was performed by a panel of 9 experts from the ARS Quality Improvement Committee.ResultsThe final QI‐prioritized list of sinonasal diseases are as follows: chronic rhinosinusitis (CRS) (mean score = 8.9), recurrent acute rhinosinusitis (RARS) (mean score = 7.9), sinonasal neoplasms (mean score = 7.0), anatomic nasal obstruction (mean score = 5.9), refractory epistaxis (mean score = 5.2), complicated acute rhinosinusitis (mean score = 5.2), chronic nonallergic rhinitis (mean score = 4.4), orbital disease (mean score = 4.3), uncomplicated acute rhinosinusitis (mean score = 4.1), and allergy/allergic rhinitis (mean score = 3.7).ConclusionThe three most important disease categories for QI from the perspective of the specialty of rhinology were CRS, RARS, and sinonasal neoplasms. Future studies need to define and validate quality metrics for each of these important disease categories in order to facilitate appropriate measurement and improvement initiatives.
Racial and Ethnic Variation in Perceptions of VA Mental Health Providers are Associated With Treatment Retention Among Veterans With PTSD
Spoont, Michele , Nelson, David , Ryn, Michelle van , Alegrı́a, Margarita , van Ryn, Michelle

Mayo Clinic

Medical Care | August 11, 2017 | Volume: 55 | Issue: Suppl 2 | Pages: S33-S42

10.1097/mlr.0000000000000755 | PMID 28806364 Get It

Background: Veterans with posttraumatic stress disorder (PTSD) who seek mental health care in the Veterans Health Administration frequently discontinue treatment prematurely. Early discontinuation of mental health treatment is more common among Veterans with PTSD who are of minority race or ethnicity. Objectives: To determine whether retention in individual therapy or pharmacotherapy among Veterans with PTSD are associated with patients’ ratings of their mental health providers, and if those associations differ depending on Veteran race or ethnicity. Research Design: Latino, African American, and white Veterans (n=2452) who participated in a prospective national cohort study of Veterans with PTSD at the beginning of an episode of care were surveyed immediately following Veterans’ PTSD diagnoses and 6 months later. Pharmacy and mental health service utilization were abstracted from Veterans Health Administration administrative databases for 6 months postdiagnosis. Retention in treatments were modeled using logistic regression among Veterans who initiated individual therapy or pharmacotherapy. Demographics, treatment need, treatment-related beliefs, treatment process measures, and ratings of mental health providers were considered as predictors. Results: Ratings of mental health providers, more than treatment beliefs, were associated with treatment retention. Among African American Veterans, retention in pharmacotherapy was reduced if the provider was perceived as not having helped manage medication side-effects (odds ratio, 0.36; confidence interval, 0.16–0.80). All Latino Veterans but one (99% or n=64) who rated their therapist as not caring discontinued individual psychotherapy. Conclusions: Ratings of mental health providers were associated with treatment retention. The salience of specific provider behaviors to treatment retention varied by Veteran race or ethnicity.
Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials
Lakshman, Arjun , Abeykoon, Jithma P. , Kumar, Shaji , Dingli, David , Gonsalves, Wilson I. , Leung, Nelson , Kourelis, Taxiarchis , Go, Ronald S. , Lacy, Martha Q. , Hobbs, Miriam, Lin, Yi , Warsame, Rahma , Lust, John A., Fonder, Amie , Hwa, Yi L. , Hayman, Suzanne R. , Russell, Stephen J. , Kyle, Robert A. , Kapoor, Prashant , Buadi, Francis K. , Gonsalves, Wilson , Leung, Nelson , Kourelis, Taxiarchis V, Go, Ronald S , Warsame, Rahma , Lust, John, Fonder, Amie L, Lakshman, Arjun , Russell, Stephen J , Dingli, David , Lin, Yi , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | August 11, 2017 | Volume: 92 | Issue: 11 | Pages: 1146-1155

10.1002/ajh.24883 | PMID 28799231 Get It

AbstractOutside of clinical trials, experience with daratumumab‐based combination therapies (DCTs) using bortezomib (V)/lenalidomide (R)/pomalidomide (P), and dexamethasone (d) in relapsed/refractory multiple myeloma (RRMM) is limited. We reviewed the outcomes of 126 patients who received ≥ 1 cycle of any DCT. Median age at DCT initiation was 67 (range, 43‐93) years. High‐risk cytogenetics was present in 33% patients. Median number of prior therapies was 4 (range, 1‐14) and time to first DCT from diagnosis was 4.3 years (range, 0.4‐13.0). Seventeen (13%) patients were refractory to single agent daratumumab. Fifty‐two (41%), 34 (27%), 23 (18%), and 17 (14%) received DPd, DRd, DVd and “other” DCTs, respectively. Overall response rate was 47%. Median follow‐up was 5.5 months (95% CI, 4.2‐6.1). Median progression‐free survival (PFS) was 5.5 months (95% CI, 4.2‐7.8). Median overall survival was not reached (NR) with any regimen. Median PFS (months) was worst for penta‐refractory MM (n = 8) vs quadruple refractory MM (n = 18) and others (n = 100) (2.2 [95% CI, 1‐2.4] vs 3.1 [95% CI, 2.1‐NR] vs 5.9 [95% CI, 5.0‐NR]; P < .001); those who were refractory to ≥1 agents used in the DCT vs others (4.9 [95% CI, 3.1‐6.0] vs 8.2 [95% CI, 4.6‐NR]; P = .02); and those who received >2 prior therapies vs others (5.0 months [95% CI, 3.7‐5.9] vs NR [95% CI, NR‐NR]; P = .002). Non‐hematologic toxicities included infections (38%), fatigue (32%), and infusion reactions (18%). Grade 3 or higher hematological toxicities were seen in 41% of patients. DCTs are effective in RRMM. ORR and PFS in heavily pretreated patients are lower than those reported in clinical trials.
A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies
Davies, Benjamin M. , Rikabi, Sarah , Wartolowska, Karolina , French, Anna , MacLaren, Robert E. , Williams, David , Bure, Kim, Pinedo‐Villanueva, Rafael , Mathur, Anthony , Birchall, Martin , Snyder, Evan , Reeve, Brock , Morrey, Mark, Smith, James Andrew Buchan , Morrey, Mark E. , Atala, Anthony , Brindley, David A.

Mayo Clinic

Journal of Tissue Engineering | August 11, 2017 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2041731417724413 | PMID 28835816 Get It

Cellular therapies, such as stem cell–based treatments, have been widely researched and numerous products and treatments have been developed. Despite this, there has been relatively limited use of these technologies in the healthcare sector. This study sought to investigate the perceived barriers to this more widespread adoption. An anonymous online questionnaire was developed, based on the findings of a pilot study. This was distributed to an audience of clinicians, researchers and commercial experts in 13 countries. The results were analysed for all respondents, and also sub-grouped by geographical region, and by profession of respondents. The results of the study showed that the most significant barrier was manufacturing, with other factors such as efficacy, regulation and cost-effectiveness being identified by the different groups. This study further demonstrates the need for these important issues to be addressed during the development of cellular therapies to enable more widespread adoption of these treatments.
Morbidity and Mortality in Patients With Posterior Circulation Aneurysms Treated With the Pipeline Embolization Device: A Subgroup Analysis of the International Retrospective Study of the Pipeline Embolization Device
Jang, Dong‐Kyu , Çekirge, Saruhan , Kallmes, David F. , Lylyk, Pedro , Lopes, Demetrius K. , Fiorella, David , Hanel, Ricardó A. , Levy, Elad I.

Mayo Clinic

Neurosurgery | August 11, 2017 | Volume: 83 | Issue: 3 | Pages: 488-500

10.1093/neuros/nyx467 | PMID 28945879 Get It

Abstract BACKGROUND The safety of Pipeline TM Embolization Device (PED; Medtronic Inc, Dublin, Ireland) in posterior circulation aneurysms is still controversial. OBJECTIVE To study complications associated with the treatment of posterior circulation aneurysms by conducting a subgroup analysis from the International Retrospective Study of PED registry. METHODS Data from 91 consecutive patients with 95 posterior circulation aneurysms at 17 centers between July 2008 to February 2013 were analyzed. The primary endpoint was defined as any complication leading to neurological morbidity or death. The outcome predictors were calculated using Kaplan–Meier and Cox regression methods. RESULTS The mean aneurysm size was 13.8 mm. Aneurysm types were saccular (36.8%), fusiform (29.5%), dissecting (28.4%), and others (5.3%). The median follow-up was 21.1 mo. Twelve (13.2%) patients encountered a primary endpoint event. In multivariate analysis for the primary endpoint, use of ≥3 PEDs and fusiform shape compared with other shapes had hazard ratios (HRs) of 7.77 (95% confidence interval [CI], 2.48-25.86; P = .0007) and 3.48 (95% CI, 1.06-13.39; P = .0488), respectively. The multivariate HR of aneurysm size for neurological morbidity after PED implantation was 1.11 (95% CI, 1.04-1.18; P = .0015), and HRs of ruptured aneurysm and age for neurological mortality were 8.1 (95% CI, 1.31-41.26; P = .0197) and 1.07 (95% CI, 1.02-1.15; P = .0262), respectively. Basilar artery aneurysm had an HR of 3.54 (95% CI, 1.12-14.18, P = .0529) in the univariate analysis for major outcomes. CONCLUSION PED implantation may be considered for the treatment of posterior circulation aneurysms, especially of saccular or dissecting type. Our major complications appear to be comparable to those reported previously after clipping and coiling in the literature. Neurointerventionists should consider the shape, size, rupture, and location of complex posterior circulation aneurysms as well as age and PED number before the PED placement.
Regional Variation in 30-Day Ischemic Stroke Outcomes for Medicare Beneficiaries Treated in Get With The Guidelines–Stroke Hospitals
Thompson, Michael P. , Zhao, Xin , Bekelis, Kimon , Gottlieb, Daniel J. , Schulte, Phillip J. , Xian, Ying , Lytle, Barbara L. , Reeves, Mathew J. , Schwamm, Lee H. , Smith, Eric E. , Fonarow, Gregg C. , Smith, Eric Edward

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | August 11, 2017 | Volume: 10 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.117.003604 | PMID 28798017 Get It

Background— We explored regional variation in 30-day ischemic stroke mortality and readmission rates and the extent to which regional differences in patients, hospitals, healthcare resources, and a quality of care composite care measure explain the observed variation. Methods and Results— This ecological analysis aggregated patient and hospital characteristics from the Get With The Guidelines–Stroke registry (2007–2011), healthcare resource data from the Dartmouth Atlas of Health Care (2006), and Medicare fee-for-service data on 30-day mortality and readmissions (2007–2011) to the hospital referral region (HRR) level. We used linear regression to estimate adjusted HRR-level 30-day outcomes, to identify HRR-level characteristics associated with 30-day outcomes, and to describe which characteristics explained variation in 30-day outcomes. The mean adjusted HRR-level 30-day mortality and readmission rates were 10.3% (SD=1.1%) and 13.1% (SD=1.1%), respectively; a modest, negative correlation ( r =−0.17; P =0.003) was found between one another. Demographics explained more variation in readmissions than mortality (25% versus 6%), but after accounting for demographics, comorbidities accounted for more variation in mortality compared with readmission rates (17% versus 7%). The combination of hospital characteristics and healthcare resources explained 11% and 16% of the variance in mortality and readmission rates, beyond patient characteristics. Most of the regional variation in mortality (65%) and readmission (50%) rates remained unexplained. Conclusions— Thirty-day mortality and readmission rates vary substantially across HRRs and exhibit an inverse relationship. While regional variation in 30-day outcomes were explained by patient and hospital factors differently, much of the regional variation in both outcomes remains unexplained.